ISSCR 2026 serves as a vibrant platform for showcasing nearly 1,300 scientific posters and presentations that span the full spectrum of stem cell research. Attendees gain access to breakthrough discoveries, emerging technologies, and innovative methodologies shaping the future of biomedical science. The conference fosters interdisciplinary collaboration among scientists, clinicians, ethicists, and industry leaders, creating fertile ground for cross-pollination of ideas and accelerating translational impact.

The opening plenary, curated by ISSCR President Hideyuki Okano, set an inspiring tone by featuring pioneers whose research has fundamentally transformed the field. Nobel Laureate Shinya Yamanaka, whose identification of induced pluripotent stem cells (iPSCs) revolutionized regenerative medicine, underscored the transformative potential of reprogramming adult cells to a pluripotent state. This discovery laid the groundwork for novel approaches in personalized disease models and cell replacement therapies that continue advancing toward clinical application.

Another highlight included Madeline Lancaster’s presentation on brain organoids—three-dimensional cultures derived from stem cells that recapitulate human brain development. These models are invaluable for probing complex neurodevelopmental processes and uncovering mechanisms underlying neurological disorders, offering unprecedented insights into human brain evolution and pathology.

Yukiko Gotoh’s research shed light on the molecular circuits guiding neuronal specification and connectivity formation during mammalian brain development. Her findings contribute to an enhanced understanding of neurodevelopmental disorders, elucidating how disruptions to these pathways may lead to cognitive and behavioral phenotypes.

Feng Zhang, renowned for pioneering CRISPR genome-editing technologies, discussed innovations that enhance the precision and scope of genetic engineering in stem cell contexts. Such advancements open avenues for sophisticated gene-modulation therapies targeting neurological diseases, paving the way for personalized, cell-based interventions.

Throughout the conference, participants engage with state-of-the-art tools and emerging technologies showcased in the Exhibit and Poster Hall, offering a glimpse into next-generation platforms that promise to accelerate both basic research and clinical translation.

President Okano emphasized the ISSCR community’s shared commitment to advancing science responsibly, ensuring that transformative discoveries are ethically developed for global patient benefit. As stem cell science rapidly evolves, ISSCR 2026 exemplifies a critical nexus for innovation, dialogue, and collaboration essential to realizing the therapeutic promise of regenerative medicine.

For more details on the ISSCR 2026 meeting, visit www.isscr2026.org.

Subject of Research: Stem cell research, regenerative medicine, gene editing, neurodevelopmental biology
Article Title: ISSCR 2026 Unites Leading Minds to Drive Forward Stem Cell Science and Translational Innovation
News Publication Date: Not specified
Web References: www.isscr2026.org
Image Credits: ISSCR
Keywords: Stem cell research, regenerative medicine, induced pluripotent stem cells, brain organoids, CRISPR, neurodevelopment, translational medicine

A key highlight of this forthcoming conference is the co-sponsorship by STEMCELL Technologies, a leading biotechnology enterprise that has long been integral to fostering research excellence. This partnership symbolizes a deepening synergy between scientific discovery and commercial application, reflecting the collective effort necessary to propel stem cell research from the bench toward clinical translation. STEMCELL Technologies brings to the table a portfolio of over 2,500 specialized reagents, tools, and services, which are pivotal in supporting experimental rigor and reproducibility in diverse arenas such as immunology, cancer research, and cellular therapy development.

The 2026 program under the stewardship of ISSCR President Hideyuki Okano and led by experts Fiona Doetsch and Nozomu Yachie, is set to expand its scientific scope, integrating the burgeoning field of engineering biology. This emerging discipline merges computational modeling, systems biology, and biotechnological engineering to unravel complex cellular behaviors and to devise novel therapeutic strategies. The inclusion of engineering biology underscores the transformative potential of interdisciplinary approaches in decoding stem cell mechanisms and amplifying their clinical utility.

As stem cell research accelerates, the ISSCR Annual Meeting stands as a vital platform for disseminating breakthrough findings that span from foundational biology to translational research. This dynamic forum empowers scientists to present novel insights into pluripotency, lineage specification, and stem cell niche dynamics, as well as to explore sophisticated methodologies such as single-cell transcriptomics, CRISPR-based genome editing, and organoid modeling. By fostering rigorous scientific exchange, the conference aims to bridge gaps between experimental innovation and clinical implementation.

Dr. Allen Eaves, President and CEO of STEMCELL Technologies, emphasizes the significance of collaborative networks in driving research impact. By co-sponsoring this meeting, STEMCELL Technologies champions a shared vision where academic inquiry and industrial development coalesce to expedite therapeutic breakthroughs. The Montréal venue offers a vibrant scientific milieu where over 3,500 international delegates will convene to forge strategic partnerships, engage in knowledge transfer, and spotlight next-generation biotechnologies that promise to reshape regenerative medicine landscapes.

The ISSCR 2026 Annual Meeting will spotlight multifaceted scientific discussions, ranging from stem cell-derived cellular therapies to the ethical frameworks governing research conduct. These conversations are crucial in navigating the regulatory and societal implications of stem cell applications, ensuring that advancements adhere to the highest standards of research integrity and patient safety. Furthermore, the meeting will facilitate discourse on innovations in clinical trials, including adaptive designs and biomarker integration, which are transforming the evaluation of stem cell-based interventions.

Integral to the event’s mission is the promotion of inclusivity and diversity within the global regenerative medicine community. ISSCR membership offers members exclusive registration benefits and tailored opportunities to engage with peer networks, fostering a supportive environment where emerging investigators and established scientists alike can collaborate. This inclusive ethos nurtures the exchange of ideas that inspire novel research trajectories and enhance the translational pipeline.

For scientists eager to contribute, the abstract submission deadline is February 25, 2026, inviting researchers to share oral presentations and compete for prestigious Travel and Merit Awards. A subsequent late-breaking abstract submission window will accommodate poster presentations, ensuring that the latest data and preliminary findings receive ample exposure. These mechanisms support a dynamic and responsive program that reflects the rapidly evolving nature of stem cell science.

In addition to the scientific program, ISSCR 2026 offers a comprehensive expo where companies can showcase technological innovations that underpin research excellence. This includes advanced cell culture media formulations, high-throughput screening platforms, and precision cell separation techniques that are instrumental in refining experimental workflows. Industry participation underscores the interdependence of academic research and commercial technology development, accelerating the path from laboratory discoveries to therapeutic realities.

Journalists seeking to cover the ISSCR 2026 Annual Meeting are encouraged to apply for media credentials to gain complimentary access, facilitating widespread dissemination of new knowledge and insights emerging from the conference. Broad media engagement ensures that progressive stem cell science achieves heightened visibility, attracting multidisciplinary interest and public support for regenerative medicine initiatives.

With an active global membership nearing 5,000 from over 80 countries, ISSCR remains the premier international organization dedicated to advancing stem cell research and its clinical translation. The society’s commitment to fostering scientific excellence and ethical integrity continues to propel the field into new frontiers, making ISSCR 2026 a pivotal event for shaping the future trajectories of stem cell biology and regenerative therapies.

This upcoming ISSCR Annual Meeting is set to be a defining chapter in global stem cell science, aligning pioneering research with technological innovation and clinical ambition. As the community converges in Montréal, the event will not only reflect the current state of the art but will also chart new directions for regenerative medicine, inspiring collaborations that will ultimately transform patient care worldwide.

Subject of Research: Stem cell research, regenerative medicine, engineering biology, translational and clinical stem cell applications.

Article Title: ISSCR 2026 Annual Meeting to Drive Breakthroughs in Stem Cell Science and Regenerative Medicine

News Publication Date: Not specified (content relevant to 2026 event information)

Web References:

• ISSCR 2026 Annual Meeting
• STEMCELL Technologies
• ISSCR Membership

Image Credits: International Society for Stem Cell Research (ISSCR)

Keywords: Stem cell research, translational research, clinical research, research organizations, research ethics, cell therapies, clinical trials, drug development

The alliance between the ISSCR and the Novo Nordisk Foundation underscores a shared, resolute commitment to propelling stem cell research from foundational science toward innovative clinical applications. The conference’s platform will provide an unparalleled opportunity to showcase pioneering research that embraces both basic and translational approaches. By bringing together a global cohort of experts, the meeting will foster interdisciplinary exchanges that catalyze breakthroughs in regenerative medicine therapies, targeting some of the most pressing health challenges of our time.

Fiona Doetsch, who currently serves as ISSCR vice president and will assume the presidency at the time of the meeting, expressed enthusiasm over the enduring partnership with the Novo Nordisk Foundation. She highlighted the significance of the Annual Meeting as an incubator for scientific innovation and networking. Doetsch emphasized the inclusive nature of the event, designed to empower investigators at all career stages. The meeting will champion early-career scientists while simultaneously engaging senior researchers, offering a rich environment for nurturing the next generation of leaders in the field.

From a biomedical research standpoint, stem cell science represents a frontier where fundamental biology meets translational potential. By harnessing pluripotent stem cells’ ability to differentiate into diverse cell types, scientists aim to repair or replace damaged tissues, revolutionizing treatment strategies for degenerative diseases, organ failure, and traumatic injuries. The ISSCR 2028 meeting will focus on these technological advancements, including gene-editing innovations such as CRISPR-Cas9, organoid development, and biomaterials integration for tissue engineering, all of which hold immense promise for clinical translation.

Tanja Xenia Pedersen, vice president for Biomedical Research at the Novo Nordisk Foundation, emphasized the strategic importance of hosting the Annual Meeting in Copenhagen. This event will spotlight the robust regenerative medicine ecosystem emerging within Denmark and the Nordic region, fostering global collaborations and increasing international visibility for local research endeavors. The Foundation’s philanthropic vision aligns seamlessly with the ISSCR mission by supporting scientific advancement and sustainable innovation aimed at improving human health.

The meeting will be convened at the Bella Center Copenhagen, a venue renowned for accommodating large-scale scientific events. Attendees will benefit from state-of-the-art facilities conducive to plenary sessions, workshops, and dynamic poster presentations. Abstract submissions will open in October 2027, inviting researchers worldwide to contribute their latest findings. Selected abstracts will have the opportunity to be featured as oral presentations, while merit and travel awards will be available to support promising scientists in disseminating their work.

Former ISSCR president Melissa H. Little, a leading figure in stem cell medicine and CEO of the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), expressed excitement about hosting the global community in the Nordic region. The reNEW collaboration represents a multi-institutional effort designed to accelerate translation from stem cell discoveries to viable therapies. Little anticipates that the ISSCR meeting will catalyze multidisciplinary alliances, promote knowledge exchange, and highlight key progress in developing stem cell-based therapeutic modalities.

Scientific discourse at the ISSCR Annual Meeting traditionally encompasses a wide spectrum of stem cell research topics, including embryonic stem cells, induced pluripotent stem cells (iPSCs), hematopoietic stem cells, and mesenchymal stem cells. The dialogue will also address the ethical frameworks guiding research and clinical applications, ensuring responsible stewardship of emerging technologies. Discussions around research ethics, policy implications, and public engagement will be integral components of the meeting’s program.

The ISSCR’s sustained growth to nearly 5,000 members from over 80 countries reflects the field’s expanding scientific and clinical relevance. The organization’s dedication to fostering scientific excellence and enabling translation of stem cell applications to the clinic underpins the Annual Meeting agenda. Attendees can expect sessions on novel cell therapies, gene modification techniques, tissue engineering scaffolds, and strategies to overcome immunological challenges in transplantation.

Moreover, the meeting will serve as a critical forum for addressing regulatory landscapes influencing stem cell therapies’ development and commercialization. Navigating these complex frameworks is essential for advancing safe and effective treatments while maintaining public trust. This aspect of the conference will attract stakeholders from regulatory agencies and industry, facilitating dialogue aimed at harmonizing standards and accelerating therapeutic availability.

The ISSCR 2028 Annual Meeting thus promises to be more than a scientific gathering; it will be a transformative event catalyzing global collaboration, inspiring innovation, and shaping the future trajectory of stem cell research and regenerative medicine. By uniting a diverse international community, the conference will undoubtedly leave a lasting impact on biomedical science, health policy, and patient care worldwide.

Subject of Research: Stem cell research and regenerative medicine

Article Title: ISSCR and Novo Nordisk Foundation Announce 2028 Annual Meeting in Copenhagen to Propel Global Stem Cell Science

News Publication Date: Not explicitly provided (related to announcement date)

Web References:

• https://novonordiskfonden.dk/en/
• https://www.isscr.org/upcoming-programs/isscr-2028
• https://www.bellacenter.dk/en
• http://www.isscr.org
• https://renew.science/

Keywords: Stem cell research, Basic research, Applied research, Discovery research, Translational research, Research organizations, Scientific conferences, Scientific foundations, Research ethics